As biotechs expand their outsourced clinical operations, adopting a CTMS is becoming essential to ensure CRO oversight, regulatory compliance, and real-time visibility across trials and portfolios.
Henry Galio
Advertisement
Vice President, Veeva Clinical Strategy
Articles by Henry Galio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Decision Inputs in Drug Development—Big Vs. Small Pharma: Is There a Difference?
2
Modernizing Recruitment with Data, HCP Networks, and Last Mile Support
3
Rethinking Site Selection and Oversight Amid Complex Protocols
4
ACT Brief: AI Decision-Making, Sponsor Oversight Trends, and HHS Label Changes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
